Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study. (Record no. 28944712)

MARC details
000 -LEADER
fixed length control field 01415 a2200433 4500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250518003106.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 201901s 0 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1471-2407
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1186/s12885-018-4891-7
Source of number or code doi
040 ## - CATALOGING SOURCE
Original cataloging agency NLM
Language of cataloging eng
Transcribing agency NLM
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Kim, Min Kyoung
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Date of production, publication, distribution, manufacture, or copyright notice 20190121
245 00 - TITLE STATEMENT
Title Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study.
Medium [electronic resource]
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. BMC cancer
Date of publication, distribution, etc. Oct 2018
300 ## - PHYSICAL DESCRIPTION
Extent 988 p.
Other physical details digital
500 ## - GENERAL NOTE
General note Publication Type: Journal Article
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Adult
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aged
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aged, 80 and over
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antineoplastic Agents
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Carcinoma, Non-Small-Cell Lung
General subdivision drug therapy
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cytochrome P-450 CYP3A Inducers
General subdivision therapeutic use
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Erlotinib Hydrochloride
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Female
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Liver
General subdivision drug effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Liver Neoplasms
General subdivision secondary
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Male
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Middle Aged
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Pancreatic Neoplasms
General subdivision drug therapy
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Retrospective Studies
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Yee, Jeong
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Cho, Yoon Sook
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Jang, Hong Won
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Han, Ji Min
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Gwak, Hye Sun
773 0# - HOST ITEM ENTRY
Title BMC cancer
Related parts vol. 18
-- no. 1
-- p. 988
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://doi.org/10.1186/s12885-018-4891-7">https://doi.org/10.1186/s12885-018-4891-7</a>
Public note Available from publisher's website

No items available.